AU2017341825B2 - Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders - Google Patents

Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders Download PDF

Info

Publication number
AU2017341825B2
AU2017341825B2 AU2017341825A AU2017341825A AU2017341825B2 AU 2017341825 B2 AU2017341825 B2 AU 2017341825B2 AU 2017341825 A AU2017341825 A AU 2017341825A AU 2017341825 A AU2017341825 A AU 2017341825A AU 2017341825 B2 AU2017341825 B2 AU 2017341825B2
Authority
AU
Australia
Prior art keywords
subject
compound
administration
pharmaceutically acceptable
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017341825A
Other languages
English (en)
Other versions
AU2017341825A1 (en
Inventor
Radko KOMERS
Alvin SHIH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Travere Therapeutics Inc
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Publication of AU2017341825A1 publication Critical patent/AU2017341825A1/en
Assigned to Travere Therapeutics, Inc. reassignment Travere Therapeutics, Inc. Amend patent request/document other than specification (104) Assignors: Retrophin, Inc.
Application granted granted Critical
Publication of AU2017341825B2 publication Critical patent/AU2017341825B2/en
Priority to AU2023219839A priority Critical patent/AU2023219839B2/en
Priority to AU2025271121A priority patent/AU2025271121A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017341825A 2016-10-13 2017-10-13 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders Active AU2017341825B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023219839A AU2023219839B2 (en) 2016-10-13 2023-08-22 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
AU2025271121A AU2025271121A1 (en) 2016-10-13 2025-11-21 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407860P 2016-10-13 2016-10-13
US62/407,860 2016-10-13
US201662423079P 2016-11-16 2016-11-16
US62/423,079 2016-11-16
PCT/US2017/056538 WO2018071784A1 (en) 2016-10-13 2017-10-13 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023219839A Division AU2023219839B2 (en) 2016-10-13 2023-08-22 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Publications (2)

Publication Number Publication Date
AU2017341825A1 AU2017341825A1 (en) 2019-04-11
AU2017341825B2 true AU2017341825B2 (en) 2023-06-01

Family

ID=60191503

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017341825A Active AU2017341825B2 (en) 2016-10-13 2017-10-13 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
AU2023219839A Active AU2023219839B2 (en) 2016-10-13 2023-08-22 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
AU2025271121A Pending AU2025271121A1 (en) 2016-10-13 2025-11-21 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023219839A Active AU2023219839B2 (en) 2016-10-13 2023-08-22 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
AU2025271121A Pending AU2025271121A1 (en) 2016-10-13 2025-11-21 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Country Status (10)

Country Link
US (5) US20190262317A1 (enExample)
EP (1) EP3525784A1 (enExample)
JP (4) JP2019530713A (enExample)
KR (4) KR20190077348A (enExample)
CN (5) CN114788823A (enExample)
AU (3) AU2017341825B2 (enExample)
BR (1) BR112019007576A2 (enExample)
CA (1) CA3039819A1 (enExample)
MA (1) MA46524A (enExample)
WO (1) WO2018071784A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7524167B2 (ja) * 2018-10-04 2024-07-29 トラビア セラピューティクス， インコーポレイテッド Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
CN114126712A (zh) * 2018-12-21 2022-03-01 特拉维尔治疗公司 无定形司巴森坦（sparsentan）组合物
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
IL293921A (en) 2019-12-17 2022-08-01 Chinook Therapeutics Inc Methods for treating iga kidney disease with atresantan
JP2023521169A (ja) * 2020-04-10 2023-05-23 チヌーク セラピューティクス，インコーポレイテッド 糖尿病性腎疾患の処置方法
WO2022246200A1 (en) 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
KR20240051999A (ko) 2021-08-26 2024-04-22 상하이 한서 바이오메디컬 컴퍼니 리미티드 방향족 고리 함유 생물학적 길항제, 이의 제조 방법 및 용도
AR128112A1 (es) * 2021-12-28 2024-03-27 Alchemedicine Inc Compuesto, antagonista del receptor de angiotensina ii tipo 1 y composición farmacéutica
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物
WO2024249509A1 (en) 2023-05-31 2024-12-05 Travere Therapeutics, Inc. Sparsentan for use in a method of treating iga-mediated diseases
WO2025064688A1 (en) 2023-09-20 2025-03-27 Travere Therapeutics, Inc. Sparsentan for treating immunoglobulin a nephropathy (igan)
CN118666826A (zh) * 2024-08-23 2024-09-20 成都臻拓医药科技有限公司 一种司帕生坦原料药的重结晶纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150164865A1 (en) * 2009-03-31 2015-06-18 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
EP1237888B1 (en) 1999-12-15 2006-09-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) * 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
LT3126330T (lt) * 2014-04-04 2019-04-25 Pfizer Inc. Bicikliniai kondensuoti heteroarilo arba arilo junginiai, ir jų panaudojimas kaip irak4 inhibitorių
JP7524167B2 (ja) 2018-10-04 2024-07-29 トラビア セラピューティクス， インコーポレイテッド Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150164865A1 (en) * 2009-03-31 2015-06-18 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RADKO KOMERS, HORACIO PLOTKIN: "Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease", AMERICAN JOURNAL OF PHYSIOLOGY - REGULATORY , INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY., US, vol. 310, no. 10, 15 May 2016 (2016-05-15), US , pages R877 - R884, XP055436443, ISSN: 0363-6119, DOI: 10.1152/ajpregu.00425.2015 *
YUICHI IKEDA, HIDETOSHI KUMAGAI, YOSHIHIRO MOTOZAWA, JUN-ICHI SUZUKI, ISSEI KOMURO: "Next Generation ARBs. Going Beyond Modulation of the Renin-Angiotensin System", INTERNATIONAL HEART JOURNAL, JAPAN, 1 January 2015 (2015-01-01), Japan , pages 585, XP055436552, Retrieved from the Internet <URL:https://www.jstage.jst.go.jp/article/ihj/56/6/56_15-295/_pdf/-char/en> *

Also Published As

Publication number Publication date
KR20190077348A (ko) 2019-07-03
US20210196688A1 (en) 2021-07-01
US20200281901A1 (en) 2020-09-10
US20250325523A1 (en) 2025-10-23
CN116983302A (zh) 2023-11-03
AU2023219839A1 (en) 2023-09-07
CA3039819A1 (en) 2018-04-19
JP2022141802A (ja) 2022-09-29
KR20220132030A (ko) 2022-09-29
EP3525784A1 (en) 2019-08-21
JP2025060754A (ja) 2025-04-10
JP2022137245A (ja) 2022-09-21
AU2023219839B2 (en) 2025-08-21
CN117017985A (zh) 2023-11-10
US20250325522A1 (en) 2025-10-23
JP2019530713A (ja) 2019-10-24
AU2017341825A1 (en) 2019-04-11
KR20230066644A (ko) 2023-05-16
US20190262317A1 (en) 2019-08-29
BR112019007576A2 (pt) 2019-07-02
KR102528435B1 (ko) 2023-05-03
CN117085013A (zh) 2023-11-21
WO2018071784A1 (en) 2018-04-19
AU2025271121A1 (en) 2025-12-18
KR20240162167A (ko) 2024-11-14
CN114788823A (zh) 2022-07-26
US10864197B2 (en) 2020-12-15
MA46524A (fr) 2019-08-21
CN110049764A (zh) 2019-07-23

Similar Documents

Publication Publication Date Title
US20250325523A1 (en) Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
US20220048900A1 (en) Amorphous sparsentan compositions
AU2019354784B2 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
WO2022246200A1 (en) Methods of treating kidney diseases or disorders
WO2025064688A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
BR122025008185A2 (pt) Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
AU2024279669A1 (en) Sparsentan for use in a method of treating iga-mediated diseases
CA3098302A1 (en) Methods of treating bacterial infections with minocycline

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: TRAVERE THERAPEUTICS, INC.

Free format text: FORMER NAME(S): RETROPHIN, INC.

FGA Letters patent sealed or granted (standard patent)